Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200013/S027

Alinity m HBV

Abbott Molecular, Inc. · Decision date Oct 17, 2025

FDA DECISIONP200013/S027

What did the FDA approve?

FDA records P200013/S027 as a supplement to PMA P200013, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Oct 17, 2025.

FDA approval order statement

Approval to release software Alinity m System Software version 1.9.1., which incorporates all changes, in the US for a mandatory customer software update.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Microbiology
Decision date
Oct 17, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P200013/S027
Regulatory pathway
PMA supplement
Product code
MKT
Decision code
APPR
Decision date
Oct 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hepatitis Viral B DNA Detection.

Product code
MKT
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200013/S027 received

    Application receipt date recorded by FDA.

  2. P200013/S027 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P200013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200013

Product / regulatory recordCompanyPathwayDecision dateSource
Alinity m HBVP200013/S026
Abbott Molecular, Inc.PMA supplementSep 24, 2025FDA

Explore the linked device profile

Other records with product code MKT

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HBVP150014/S056
Roche Molecular Systems, Inc.PMA supplementOct 17, 2025FDA
Hologic, Inc.PMA supplementOct 7, 2025FDA
cobas HBVP150014/S058
Roche Molecular Systems, Inc.PMA supplementSep 19, 2025FDA
cobas HBVP150014/S057
Roche Molecular Systems, Inc.PMA supplementAug 7, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records